Cite
HARVARD Citation
Höglinger, G. et al. (2021). Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet neurology. 20 (3), pp. 182-192. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Höglinger, G. et al. (2021). Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet neurology. 20 (3), pp. 182-192. [Online].